Use of a nutritional composition, food

Abstract

The application relates to the field of food technology, and particularly provides application of a nutritional composition and food. The application provides application of a nutritional composition in preparation of a product for promoting brain development; the nutritional composition comprises whey protein powder, casein glycomacropeptide and sialic acid; the mass ratio of the whey protein powder, the casein glycomacropeptide and the sialic acid is (1-30):(1-3.5):1; in the whey protein powder, the content of protein is 60-80 wt%, the content of fat is 16-22 wt%, and the content of phospholipid is 6-10 wt%. Compared with the prior art, the nutritional composition has a synergistic effect on promoting brain development, can not only promote expression of sialic acidase in the brain, but also can promote expression of brain-derived neurotrophic factor.

Description

TECHNICAL FIELD

[0001] The present application relates to the field of food technology, and more particularly, provides the application of a nutritional composition, a food. BACKGROUND

[0002] Casein Glycomacropeptide (CGMP) is a glycopeptide with 64 amino acid residues (106-109) obtained by hydrolyzing the peptide bond of Phe105-Met106 in K-casein with rennin (or pepsin). CGMP has different glycosylation and phosphorylation structures. It has many physiological activity functions and unique nutritional properties, and can be added to health foods and medical products.

[0003] Sialic acid is an important component of glycoprotein and glycolipid on cell membrane, generally located at the end of macromolecules such as glycoprotein and glycolipid. Breast milk contains 0.3-1.5 mg / ml of sialic acid, mainly in the form of bound state, including breast milk oligosaccharides, glycolipids and glycoproteins, among which breast milk oligosaccharides are the main form, accounting for 75% of the total sialic acid in breast milk. Sialic acid has many biological functions: cell proliferation, differentiation and recognition; interaction with pathogenic microorganisms, involved in immune response; promoting the development of nervous system, facilitating the formation of memory and improving learning ability. The most important sialylated oligosaccharides in breast milk are 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL). Studies have shown that the central nervous system of mammals contains a high level of sialic acid, most of which exists in gangliosides (65%), and 32% of sialic acid exists in the form of glycoprotein binding. Sialic acid and its derivatives have an important influence on neural cells, and can promote the growth of neurons and axons.

[0004] Brain-derived neurotrophic factor (BDNF) is a protein with neurotrophic effect first discovered in pig brain, belonging to a protein family called neurotrophic factors, which act on neurons in different ways. BDNF is widely distributed in tissues such as central nervous system, peripheral nervous system, endocrine system, bone and cartilage, and has a regulatory function on the growth, development, induced differentiation and synaptic connection of embryonic neurons, and plays an important role in the formation of neural network. At the same time, it also participates in activity-dependent neuronal plasticity, including post-injury repair and protection, especially the protection of the prefrontal cortex, hippocampus and other parts related to cognitive function. BDNF can act on certain neurons of the central nervous system and peripheral nervous system, helping the survival of existing neurons, promoting the growth and differentiation of new neurons and synapses.

[0005] The effect of the whey protein powder rich in protein, fat and phospholipid and the casein glycomacropeptide in combination for the expression of brain-derived neurotrophic factor and sialidase is unclear in the prior art, and further research is needed. SUMMARY

[0006] Therefore, the present application provides the application of the nutritional composition and the food, and the nutritional composition has a synergistic effect on promoting brain development.

[0007] To achieve the above-mentioned purpose, the present application adopts the following technical solutions:

[0008] The application of the nutritional composition in the preparation of a product for promoting brain development;

[0009] The nutritional composition comprises whey protein powder, casein glycomacropeptide and sialic acid.

[0010] The mass ratio of the whey protein powder, the casein glycomacropeptide and the sialic acid is (1-30):(1-3.5):1.

[0011] In the whey protein powder, the content of protein is 60-80wt%, the content of fat is 16-22wt%, and the content of phospholipid is 6-10wt%.

[0012] Preferably, the mass ratio of the whey protein powder, the casein glycomacropeptide and the sialic acid is (2-30):(1-3.3):1.

[0013] Preferably, the mass ratio of the whey protein powder, the casein glycomacropeptide and the sialic acid is (5-30):(1-3.3):1.

[0014] The present application also provides the application of the nutritional composition in the preparation of a product for promoting the expression of brain-derived neurotrophic factor.

[0015] The nutritional composition comprises whey protein powder, casein glycomacropeptide and sialic acid.

[0016] The mass ratio of the whey protein powder, the casein glycomacropeptide and the sialic acid is (1-30):(1-3.5):1.

[0017] In the whey protein powder, the content of protein is 60-80wt%, the content of fat is 16-22wt%, and the content of phospholipid is 6-10wt%.

[0018] Preferably, the mass ratio of the whey protein powder, the casein glycomacropeptide and the sialic acid is (2-30):(1-3.3):1.

[0019] Preferably, the mass ratio of the whey protein powder, the casein glycomacropeptide and the sialic acid is (5-30):(1-3.3):1.

[0020] The present application also provides use of the nutritional composition in preparing a product for promoting sialidase expression.

[0021] The nutritional composition comprises whey protein powder, casein glycomacropeptide and sialic acid.

[0022] The mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is (1-30):(1-3.5):1.

[0023] In the whey protein powder, the content of protein is 60-80wt%, the content of fat is 16-22wt%, and the content of phospholipid is 6-10wt%.

[0024] Preferably, the mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is (2-30):(1-3.3):1.

[0025] Preferably, the mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is (5-30):(1-3.3):1.

[0026] The present application also provides a food product comprising the nutritional composition.

[0027] The nutritional composition comprises whey protein powder, casein glycomacropeptide and sialic acid.

[0028] The mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is (1-30):(1-3.5):1.

[0029] In the whey protein powder, the content of protein is 60-80wt%, the content of fat is 16-22wt%, and the content of phospholipid is 6-10wt%.

[0030] Preferably, the food product comprises dairy products.

[0031] The present application also provides a nutritional composition comprising whey protein powder, casein glycomacropeptide and sialic acid.

[0032] The mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is (1-30):(1-3.5):1.

[0033] In the whey protein powder, the content of protein is 60-80wt%, the content of fat is 16-22wt%, and the content of phospholipid is 6-10wt%.

[0034] The nutritional composition of whey protein powder and casein glycomacropeptide rich in protein, fat and phospholipid provided by the present application has a synergistic effect on promoting the expression of sialidase in the brain and the expression of brain-derived neurotrophic factor. BRIEF DESCRIPTION OF DRAWINGS

[0035] Figure 1 is a daily weight data chart of each group of piglets in the embodiment of the present application;

[0036] Figure 2 is a daily weight gain of each group of piglets in the embodiment of the present application;

[0037] Figure 3 is a daily feed intake of each group of piglets in the embodiment of the present application;

[0038] Figure 4 is a distance moved in a T maze of each group of piglets in the embodiment of the present application;

[0039] Figure 5 is a speed moved in a T maze of each group of piglets in the embodiment of the present application;

[0040] Figure 6 is a proportion of each group of piglets completing learning in a T maze per day in the embodiment of the present application;

[0041] Figure 7 is an expression level of prefrontal cortex ST8SIA4 and GNE mRNA of each group of piglets in the embodiment of the present application;

[0042] Figure 8 is an expression level of liver tissue ST8SIA4 and GNE mRNA of each group of piglets in the embodiment of the present application;

[0043] Figure 9 is a prefrontal cortex BDNF mRNA expression level of each group of piglets in the embodiment of the present application. DETAILED DESCRIPTION

[0044] The technical solutions of the present application will be described clearly and completely below in combination with the embodiments of the present application. Obviously, the described embodiments are only some of the embodiments of the present application, not all. Based on the embodiments in the present application, all other embodiments obtained by those skilled in the art without creative labor fall within the scope of protection of the present application.

[0045] Use of a nutritional composition in the preparation of a product for promoting brain development;

[0046] The nutritional composition comprises whey protein powder, casein glycomacropeptide and sialic acid;

[0047] The mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is (1-30):(1-3.5):1;

[0048] The content of protein in the whey protein powder is 60-80 wt%, the content of fat is 16-22 wt%, and the content of phospholipid is 6-10 wt%.

[0049] Preferably, the mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is (2-30):(1-3.3):1.

[0050] Preferably, the mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is (5-30):(1-3.3):1.

[0051] Preferably, the mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is (6-17):(2-3):1.

[0052] In one embodiment of the present application, the mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is 6:2:1.

[0053] In one embodiment of the present application, the mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is 17:3:1.

[0054] Preferably, the content of protein in the whey protein powder is 69-76 wt%, the content of fat is 16-22 wt%, and the content of phospholipid is 6-10 wt%.

[0055] The present application also provides use of the nutritional composition in preparation of a product for promoting expression of brain-derived neurotrophic factor.

[0056] The nutritional composition comprises whey protein powder, casein glycomacropeptide and sialic acid.

[0057] The mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is (1-30):(1-3.5):1.

[0058] The content of protein in the whey protein powder is 60-80 wt%, the content of fat is 16-22 wt%, and the content of phospholipid is 6-10 wt%.

[0059] Preferably, the mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is (2-30):(1-3.3):1.

[0060] Preferably, the mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is (5-30):(1-3.3):1.

[0061] Preferably, the mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is (6-17):(2-3):1.

[0062] In one embodiment of the present application, the mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is 6:2:1.

[0063] In one embodiment of the present application, the mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is 17:3:1.

[0064] Preferably, the whey protein powder has a protein content of 69-76 wt%, a fat content of 16-22 wt%, and a phospholipid content of 6-10 wt%.

[0065] It has been demonstrated by the embodiments of the present application that the nutritional composition provided by the present application can promote the expression of brain-derived neurotrophic factor.

[0066] The present application also provides use of the nutritional composition in the preparation of a product for promoting the expression of sialidase.

[0067] The nutritional composition comprises whey protein powder, casein glycomacropeptide and sialic acid.

[0068] The mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is (1-30):(1-3.5):1.

[0069] The whey protein powder has a protein content of 60-80 wt%, a fat content of 16-22 wt%, and a phospholipid content of 6-10 wt%.

[0070] In the present application, the nutritional composition described above can promote the expression level of prefrontal cortex ST8SIA4 and GNE mRNA.

[0071] Preferably, the mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is (2-30):(1-3.3):1.

[0072] Preferably, the mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is (5-30):(1-3.3):1.

[0073] Preferably, the mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is (6-17):(2-3):1.

[0074] In one embodiment of the present application, the mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is 6:2:1.

[0075] In one embodiment of the present application, the mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is 17:3:1.

[0076] Preferably, the whey protein powder has a protein content of 69-76 wt%, a fat content of 16-22 wt%, and a phospholipid content of 6-10 wt%.

[0077] The present application also provides a food product comprising the nutritional composition;

[0078] The nutritional composition comprises whey protein powder, casein glycomacropeptide, and sialic acid;

[0079] The whey protein powder, casein glycomacropeptide, and sialic acid are in a mass ratio of (1-30):(1-3.5):1.

[0080] The whey protein powder has a protein content of 60-80 wt%, a fat content of 16-22 wt%, and a phospholipid content of 6-10 wt%.

[0081] Preferably, the food product comprises a dairy product.

[0082] In the present application, the food product comprises a dairy product; the food product is one or more of a dairy product, a cooking product, a food product for infants, a food product for pregnant or postpartum women, a food product for juveniles, a food product for adults and the elderly, a nutritional formula product, or a pet food product.

[0083] The dairy product is a liquid dairy product, a formula milk powder, a milk tablet, or a cheese.

[0084] The food product of the present application can be in the form of a beverage, a biscuit, a cake, or a confectionery product.

[0085] The infant in the food product for infants of the present application refers to an infant from birth to before 3 years old; the juvenile in the food product for juveniles refers to a juvenile from 3 years old to before 18 years old.

[0086] The present application also provides a nutritional composition comprising whey protein powder, casein glycomacropeptide, and sialic acid;

[0087] The whey protein powder, casein glycomacropeptide, and sialic acid are in a mass ratio of (1-30):(1-3.5):1.

[0088] The whey protein powder has a protein content of 60-80 wt%, a fat content of 16-22 wt%, and a phospholipid content of 6-10 wt%.

[0089] Preferably, the whey protein powder, casein glycomacropeptide, and sialic acid are in a mass ratio of (2-30):(1-3.3):1.

[0090] Preferably, the whey protein powder, casein glycomacropeptide, and sialic acid are in a mass ratio of (5-30):(1-3.3):1.

[0091] Preferably, the mass ratio of the whey protein powder, casein glycomacropeptide and sialic acid is (6-17):(2-3):1.

[0092] The present application takes newborn piglets as animal models, uses whey protein powder, casein glycomacropeptide and sialic acid rich in protein, fat and phospholipid to feed piglets, evaluates the learning and memory ability level of the piglets through T-maze behavior training and testing, and observes the brain gray matter and white matter volume of the piglets through brain imaging examination. The expression of key enzymes in sialic acid metabolism and brain-derived neurotrophic factor is analyzed.

[0093] The nutritional composition provided by the present application, which is rich in protein, fat and phospholipid, has a synergistic effect on promoting the expression of sialic acid enzyme in the brain and the expression of brain-derived neurotrophic factor.

[0094] In order to further illustrate the present application, the following examples are used for detailed description. The raw materials used in the following examples of the present application are all commercially available goods.

[0095] Example

[0096] 1.1 Sample

[0097] The nutritional composition of the present application is composed of whey protein powder, casein glycomacropeptide and sialic acid. In the examples, the whey protein powder is whey protein powder A, and the casein glycomacropeptide and sialic acid are provided by whey protein powder B.

[0098] In the whey protein powder A, the protein content is 69-76wt%, the fat content is 16-22wt%, and the phospholipid content is 6-10wt%; in the whey protein powder B, the content of casein glycomacropeptide is 60-80wt%, and the content of sialic acid is 4-6wt%.

[0099] According to the nutritional needs of newborn piglets, various required nutrients are added to prepare a basic formula milk powder to ensure the normal growth of piglets. The specific formula of the basic formula milk powder is shown in Table 1.

[0100] Table 1

[0101]

[0102]

[0103] On the premise of the basic formula powder, the dosage and proportion of the whey protein powder A and the whey protein powder B are adjusted to finally form 8 kinds of formulas, which are shown in Table 2.

[0104] Table 2

[0105]

[0106]

[0107] 1.2 Main reagent / kit information

[0108] Table 3

[0109]

[0110] 2 Preparation

[0111] 2.1 Experimental animals

[0112] Newborn 2-day-old normal male piglets were used in the experiment. The piglets weighed between 1.3-2.0 kg, and 10 piglets were included in each experimental group, for a total of 80 piglets.

[0113] 2.2 Animal rearing conditions

[0114] The piglet rearing conditions were in accordance with the People's Republic of China National Standard GB14925-2010, specifically:

[0115] Temperature: room temperature 16-26℃;

[0116] Humidity: relative humidity 40-70%;

[0117] Light: artificial lighting, 12 hours of light and dark alternation;

[0118] Air changes: ≥8 times / hour, 100% fresh air;

[0119] Feeding method: 5 times a day, feeding time at 9am, 1pm, 5pm, 9pm and 1am.

[0120] 3 Experimental design

[0121] 3.1 Animal enrollment and rearing

[0122] Newborn male piglets 2 days old, weighing 1.3-2.0 kg, were selected, and 5-10 piglets were included in each batch according to the sow's birth situation. The daily feeding amount was adjusted according to the piglet's weight on the day. Warm water (37-40℃) was used to prepare the milk, and the milk was prepared every 4-5 hours. The piglets were reared to the 30th day after birth.

[0123] 3.2 Grouping information

[0124] Table 4

[0125]

[0126]

[0127] 3.3 Physiological indicators of piglets

[0128] The fasting body weight and food intake of piglets were recorded every morning during the experiment. Brain MRI scanning was performed on the 29th day of feeding, and brain tissue and intestinal samples were collected on the last day of the experiment. Brain weight gain, expression of key factors in brain development pathways, intestinal morphology, and expression of sialic acid metabolism enzymes in the brain and liver were detected.

[0129] 3.4 Behavioral indicators of piglets

[0130] On the 15th day of the experimental intervention, a 5-day T-maze behavioral experiment was started. Piglets were randomly placed at the south or north entrance of the maze, and their task was to find the corresponding food reward in the east or west direction within 60 seconds. Each piglet was tested 10 times on the 1st and 5th days, and the number of times and time taken to complete the task, the number of piglets that completed the task, the correct rate, the task completion rate, and the movement speed and distance were recorded. All personnel involved in the behavioral experiment were unaware of the dietary intervention groups.

[0131] 4 Test results

[0132] 4.1 Physiological indicators of piglets

[0133] 1) Body weight indicators

[0134] The initial body weight of piglets was recorded at the time of enrollment, and the body weight of piglets was recorded at the same time every day during the test phase to track changes in piglet body weight (e.g. Figure 1 ).

[0135] Analysis of piglet body weight gain found that there was no significant difference in body weight gain during the experiment, indicating that the test formula can meet the normal growth needs of piglets (e.g. Figure 2 ).

[0136] 2) Food intake

[0137] Analysis of piglet food intake found that daily food intake was positively correlated with body weight, with consistent trends in both, and no significant differences between groups, indicating that the test formula does not affect daily food intake of piglets (e.g. Figure 3 )

[0138] 4.2 Behavior

[0139] T-maze is a behavioral experiment method for evaluating spatial memory ability, mainly used for testing discriminative learning and memory and reference memory of animals.

[0140] Moving distance and speed:

[0141] According to the moving distance and time of the piglets in the T-maze, it was found that the moving distance of the piglets in the T-maze gradually decreased and the moving speed gradually increased with the increase of the feeding days of the tested formula, but the difference between each group was not significant, indicating that the physical fitness of the animals in each group was at a similar level. Figure 4 、 Figure 5 )

[0142] The learning completion situation of the maze:

[0143] The correct rate of each piglet per day was more than 80% was defined as the completion of learning, and the results showed that the proportion of piglets completing learning in each group increased with the increase of the feeding time of the tested formula, and the proportion of the control group completing learning was lower than that of other test groups. Compared with the control group, examples 1-7 (i.e. compositions 1-7 in table 4) can significantly improve the proportion of piglets completing learning, and the proportion of piglets completing learning has exceeded 50% on the 5th day of intervention, while the proportion of the control group completing learning on the 5th day is still lower than 50%.(As Figure 6 )

[0144] Analyzing the results of the last day of T-maze test of each group of piglets, it was found that the mass ratio of whey protein powder A, casein glycomacropeptide and sialic acid (whey protein powder A + whey protein powder B group) had a synergistic effect. Compared with whey protein powder A (examples 1 and 2) and whey protein powder B (example 4), the whey protein powder A + whey protein powder B group (examples 5 and 6) had a better effect on improving the proportion of piglets completing learning. However, the high concentration of whey protein powder A + whey protein powder B group (example 7) did not show a synergistic effect compared with whey protein powder A (example 3) and whey protein powder B group (example 4).(As shown in table 1, table 2) Table 1 the proportion of animals completing learning in each group during the whole test period

[0145]

[0146] Table 2 synergistic effect of whey protein powder A + whey protein powder B on improving the proportion of completing learning

[0147]

[0148] The proportion of animals that did not complete learning during the entire test period was analyzed, and it was also found that the mass ratio of whey protein powder A, casein glycomacropeptide and sialic acid (whey protein powder A + whey protein powder B group) was (6-17):(2-3):1 had a synergistic effect. Compared with whey protein powder A (Example 2) and whey protein powder B group (Example 4), the whey protein powder A + whey protein powder B group (Example 6) was more effective in reducing the proportion of incomplete learning. However, the high concentration of whey protein powder A + whey protein powder B group (Example 7) did not show a synergistic effect compared with the whey protein powder A group (Example 3) and the whey protein powder B group (Example 4).

[0149] (As shown in Table 3, Table 4)

[0150] Table 3 Proportion of animals that did not complete learning during the entire test period

[0151]

[0152] Table 4 Synergistic effect of whey protein powder A + whey protein powder B

[0153]

[0154] 4.3 Expression of sialic acid metabolic enzymes

[0155] (1) Expression level of prefrontal cortex ST8SIA4 and GNE mRNA

[0156] Compared with the control group, the expression levels of prefrontal cortex sialidase ST8SIA4 and GNE enzyme mRNA in the brain of the Example 2, Example 3, Example 5, Example 6 and Example 7 groups were significantly increased, indicating that adjusting the mass ratio of whey protein powder A + whey protein powder B can significantly promote the development of piglet brain, and this index has a good corresponding relationship with the behavior data, which can to some extent explain the reason why the animals in the example group have better behavior performance. In addition, it was found that the mass ratio of whey protein powder A, casein glycomacropeptide and sialic acid (whey protein powder A + whey protein powder B group) was (6-17):(2-3):1 had a synergistic effect. Compared with the whey protein powder A group (Example 1 and 2) and the whey protein powder B group (Example 4), the whey protein powder B group (Example 5 and 6) was more effective in increasing the expression levels of sialidase ST8SIA4 and GNE enzyme mRNA. However, the whey protein powder B group (Example 7) did not show a synergistic effect compared with the whey protein powder A group (Example 3) and the whey protein powder B group (Example 4). Figure 7 )

[0157] (2) Expression level of liver tissue ST8SIA4 and GNE mRNA

[0158] The expression levels of sialidase ST8SIA4 and GNE enzyme mRNA in the liver were analyzed, and the results showed that the expression levels of sialidase and N-acetylmannosamine kinase in the liver were significantly lower than those in the brain, and there was no significant difference between each group. It is shown that adjusting the whey protein powder A + whey protein powder B group can significantly improve the expression level of sialidase ST8SIA4 and GNE enzyme mRNA in the brain of piglets, thereby promoting the development of the brain of piglets, and this index has a good corresponding relationship with the behavior data, which can explain the reason why the animals in the example group have better behavior performance to a certain extent. Figure 8 )

[0159] 4.4 Expression of BDNF mRNA in prefrontal cortex of piglets

[0160] Brain-derived neurotrophic factor (BDNF) is a protein with neurotrophic effect first discovered in the pig brain. BDNF is widely distributed in tissues such as central nervous system, peripheral nervous system, endocrine system, bone and cartilage, but is mainly expressed in the central nervous system, with the highest content in hippocampus and cortex. BDNF has the effects of increasing synaptic plasticity, promoting neurogenesis, especially hippocampal neurogenesis, and promoting cell survival.

[0161] The present application tests the expression of BDNF mRNA in the prefrontal cortex of each group. Compared with the control group, the example groups 1-7 all increase the mRNA expression of BDNF in the prefrontal cortex Figure 9 ), which shows that adjusting the whey protein powder A + whey protein powder B group can promote the development of the brain of piglets, and this index has a good corresponding relationship with the behavior data, which can explain to a certain extent the reason why the animals in the example group have better behavior performance. In addition, it is found that the mass ratio of whey protein powder A, casein glycomacropeptide and sialic acid (whey protein powder A + whey protein powder B group) is (6-17):(2-3):1, which has a synergistic effect. Compared with the whey protein powder A group (examples 1 and 2) and the whey protein powder B group (example 4), the whey protein powder A + whey protein powder B group (examples 5 and 6) has a higher expression of BDNF in the brain.

[0162] The above description of the disclosed examples enables one skilled in the art to make or use the application. Various modifications to these examples will be readily apparent to those skilled in the art, and the generic principles defined herein can be applied to other examples without departing from the spirit or scope of the application. Thus, the present application is not to be limited to the examples shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. Application of nutritional compositions in the preparation of products that promote brain development; The nutritional composition includes whey protein powder, casein glycomacropeptide, and sialic acid; The mass ratio of whey protein powder, casein glycomacropeptide and sialic acid is (6-17):(2-3):1; The whey protein powder contains 69-76 wt% protein, 16-22 wt% fat, and 6-10 wt% phospholipids.

2. The application according to claim 1, characterized in that, Application of the nutritional composition in the further preparation of products that promote the expression of brain-derived neurotrophic factor; The nutritional composition includes whey protein powder, casein glycomacropeptide, and sialic acid; The mass ratio of whey protein powder, casein glycomacropeptide and sialic acid is (6-17):(2-3):1; The whey protein powder contains 69-76 wt% protein, 16-22 wt% fat, and 6-10 wt% phospholipids.

3. The application according to claim 1, characterized in that, Application of nutritional compositions in the further preparation of products that promote sialidase expression; The nutritional composition includes whey protein powder, casein glycomacropeptide, and sialic acid; The mass ratio of whey protein powder, casein glycomacropeptide and sialic acid is (6-17):(2-3):1; The whey protein powder contains 69-76 wt% protein, 16-22 wt% fat, and 6-10 wt% phospholipids.

4. A nutritional composition, characterized in that, Including whey protein powder, casein glycomacropeptide, and sialic acid; The mass ratio of whey protein powder, casein glycomacropeptide and sialic acid is (6-17):(2-3):1; The whey protein powder contains 69-76 wt% protein, 16-22 wt% fat, and 6-10 wt% phospholipids.

5. Food products, characterized in that, Includes nutritional compositions; The nutritional composition includes whey protein powder, casein glycomacropeptide, and sialic acid; The mass ratio of whey protein powder, casein glycomacropeptide and sialic acid is (6-17):(2-3):1; The whey protein powder contains 69-76 wt% protein, 16-22 wt% fat, and 6-10 wt% phospholipids.

Images